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Abstract
Background: Available data on the effects of a fermented soy product enriched with Enterococcus
faecium and Lactobacillus Jugurti on circulating lipids and adiposity are not completely settled. This
study aimed to observe the effects of a fermented soy product enriched with Enterococcus faecium
and Lactobacillus Jugurti on central obesity and dyslipidemia control in Wistar adult male rats.
Methods: Over a period of 8 weeks, animals had "ad libitum" food intake and water consumption
as well as body weight and food consumption was monitored. The animals were assigned to four
different experimental groups: Control Group (C); Control + Fermented Product Group (CPF);
Hypercholesterolemic diet group (H); and Hypercholesterolemic + Fermented Product Group
(HPF). The HPF and CPF groups received an intragastric administration of 1 ml of fermented
product daily. After the experimental period the animals were killed by decapitation, blood was
collected to measure cholesterol, triglycerides and HDL-cholesterol plasma concentration.
Adipocyte circumference, lipolysis and lipogenis rates were measures using epididymal and
retroperitoneal white adipose tissues.
Results: The results demonstrated that 1 ml/day/rat of the fermented soy product promoted
important benefits such as reduced cholesterolemia in hypercholesterolemic diet group and the
adipocyte circumference in both control and hypercholesterolemic diet group.
Conclusion: The fermented soy product enriched with Enterococcus faecium and Lactobacillus
Jugurti decreased circulating lipids levels and reduced adipocyte area in rats.
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The term probiotic refers to live micro-organisms which
when administered in adequate amounts confer a health
benefit on the host [1]. Probiotic bacteria have been the
focus of much scientific and commercial interest due to a
range of possible health effects of these bacteria such as on
lipid metabolism [2,3]. The most widely studied probiotic
bacteria were Lactobacillus GG, Lactobacillus acidophilus,
Bifidobacterium bifidum and Enterococcus faecium [2-4].
Probiotic dairy products are considered to have functional
properties because the probiotic bacteria added to the reg-
ular fermentation cultures provide therapeutic benefits
such as modification of the immune system, reduction in
cholesterol, alleviation from lactose intolerance and faster
relief from diarrhea [5].
Available data on the effects of probiotic bacteria on lipid
metabolism are controversial. It has been reported that
Lactobacillus acidophilus [6] or Streptococcus faecalis [7] had
hypocholesterolemic functions and the cholesterol-lower-
ing mechanism depends heavily on binding of dietary
cholesterol by Lactobacillus acidophilus or Streptococcus fae-
calis. Zacconi et al. [8] shown that Enterococcus faecium had
a higher hypocholesterolemic effect in axenic mice than
Lactobacillus acidophilus. In another study, L. acidophilus
and a probiotic mixture decreased serum cholesterol con-
centration of rats fed with fat-and cholesterol-enriched
diet while the Streptococcus faecalis failed to promote this
effect [9]. On the other hand, in mice fed with control diet
[10] and in rats fed with hypertriglyceridemic diet [11] the
L. acidophilus had no effect on plasma cholesterol level. In
a normocholesterolemic women and men, fermented
milk with a bacteria culture containing Enterococcus fae-
cium promoted a rapid reduction of LDL-cholesterol, but
during a long-term intake (6 month) the reduction of
LDL-cholesterol was similar to the placebo product [12].
Nowadays the soybean is another alimentary source that
gets attention from the scientific community. Several
studies have been shown that the soy protein, with or
without dietary cholesterol, lowers plasma cholesterol
and triacylglycerol concentrations in rats [13-15]. In con-
trast, Moundras et al. [16] reported that when rats were
fed soybean protein at a suboptimal level (13%), serum
cholesterol concentration was significantly higher than
that in rats fed with 13% casein diet, and this higher cho-
lesterol level was counteracted by supplementation of the
diet with 0.4% methionine.
Some studies in human subjects have shown a significant
hypocholesterolemic effect of soy protein in hypercholes-
terolemic subjects [17-20]. However, the hypocholestero-
lemic effect of soy protein also has been shown to be
minimal or negligible in normocholesterolemic subjects
[21,22]. In addition, it has been reported that the soy pro-
tein versus the casein diet can reduce body fat and serum
insulin levels in rats [23].
Manzoni et al. [24], reported that the soy product fer-
mented by Enterococcus faecium and Lactobacillus Jugurti
supplemented with isoflavones had beneficial effects on
white adipose tissue in juvenile male rats, leads to a
decrease in adipocyte size. However, the consequences of
Enterococcus faecium and soy protein intake on circulating
lipids and adiposity area are not completely settled. In this
sense, the purpose of the present study was to examine the
effect of ferment soy product enriched with Enterococcus
faecium and Lactobacillus Jugurti in rats fed with control
diet or hypercholesterolemic diet on circulating lipids lev-
els and adipocyte area.
Results
Percentage of Body Weight Gain and Total Food Intake
The results of body weight and food intake are shown in
Table 1. The percentage of body weight gain and total
food intake were increased in H group as compared to the
C and HPF groups. No significant differences in the per-
centage of body weight and total food intake were
observed among C, CPF, and HPF groups.
Retroperitoneal and Epididymal adipose tissues
Table 2 shows that there were no significant differences
between C and CPF groups when RET (absolute and rela-
tive) and EPI (relative) weight as compared. In the HPF
group the RET and EPI (absolute and relative) weight were
lower than in H group.
A significant reduction was observed in RET and EPI adi-
pocyte circumference when CPF and HPF were compared
with C and H groups (Table 3 and Figure 1 and 2).
Measurements of the lipogenesis and lipolysis rate
The fermented soy product treatments significantly
decreased lipogenesis rate in RET, EPI and Liver when H
and HPF were compared. In CPF group, it was observed
that RET and EPI lipogenesis rates were decreased when
Table 1: Body weight gain (%) and the total food intake (g) in rats 
fed different diets during 8 weeks.
Group Body weight gain Total food intake
C 64.06 ± 4.18 1108 ± 55.04
CPF 73.55 ± 1.99 1193 ± 21.84
H 94.86 ± 3.64+ 1405 ± 33.64+
HPF 77.44 ± 2.26* 1250 ± 34.50*
Values are means ± SEM (n = 8).*p < 0.05 comparing C × CPF and H 
× HPF; +p < 0.05 comparing C × H. Control Group (C); Control + 
Fermented Product Group (CPF); Hypercholesterolemic Diet Group 
(H); and Hypercholesterolemic + Fermented Product Group (HPF).Page 2 of 9
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ences were observed in liver lipogenesis rate (Table 4).
We observed a significant increase in lipolysis rate (RET
and EPI) in the HPF group when compared with H. When
C and CPF groups were compared it was observed an
increase only in RET lipolysis rate (Table 5).
Plasma lipids
A significant TC and plasma TG is noted higher in com-
paring the H (108.67 ± 5.22; 177.83 ± 15.78) to the C
Group (62.17 ± 3.07; 122.67 ± 15.08). Rats treated with
hypercholesterolemic diet plus fermented product (HPF)
presented a significant reduction of circulating cholesterol
and triglyceride levels as compared to hypercholestero-
lemic diet group (Table 6).
Fermented soy product in HPF group tended to an
increase (p = 0,08) in HDL-cholesterol concentration
compared with H group. However, the difference was
only significant when C group was compared with CPF
group (Table 6).
Discussion
In the present study, feeding rats with hypercholestero-
lemic diet resulted in a significant increase in food intake
and body weight gain. On the other hand, previous
reports did not show a difference significantly in food
intake of rats fed chow diet and hypercholesterolemic diet
[24-27]. Probably this could be accounted by the differ-
ence of the period of treatment and the amount of choles-
terol present in the diet, since in our study the period of
treatment was longer and the concentration of cholesterol
was lower than made by the others [24-27]. In spite of
that, the diet used in the present study was able to pro-
mote hypercholesterolemia and increase plasma triglycer-
ides around 45% in rats, without modify HDL-cholesterol
concentration.
This study demonstrated that a cholesterol-rich diet can
significantly increase body weight gain, probably because
of the increased food intake, which can cause dyslipi-
demia and obesity because of the additional cholesterol in
its properties [28]. Several animal and human studies
have confirmed the hypercholesterolemic properties of a
cholesterol diet, which include increasing TC, TG, and
alterations in the lipoprotein pattern, however, the mech-
anisms of which remain under study [28-30].
In rats, the mechanisms that prevent dyslipidemia are due
to the reduction of the feedback inhibition of cholesterol
biosynthesis and increased bile acid excretion, leading to
a minor elevation of serum cholesterol after a cholesterol-
enriched diet. [31]. However, cholic acid addition to the
Table 2: Absolute (g) and Relative (g/100 g b.w) weight of the 
Retroperitoneal and Epididymal White Adipose Tissue in rats 
fed different diets during 8 weeks.
Retroperitoneal Epididymal
Absolute Relative Absolute Relative
C 3.73 ± 0.29 0.87 ± 0.06 3.20 ± 0.40 1.23 ± 0.05
CPF 4.28 ± 0.34 1.02 ± 0.07 4.63 ± 0.33* 1.01 ± 0.07
H 5.34 ± 0.76 1.09 ± 0.17+ 4.17 ± 0.43+ 0.90 ± 0.08+
HPF 3.55 ± 0.43* 0.88 ± 0,09* 2.40 ± 0.14* ° 0.66 ± 0.04*
Values are means ± SEM (n = 8).*p < 0.05 comparing C × CPF and H 
× HPF; +p < 0.05 comparing C × H; °p < 0.05 comparing CPF × HPF. 
Control Group (C); Control + Fermented Product Group (CPF); 
Hypercholesterolemic Diet Group (H); and Hypercholesterolemic + 
Fermented Product Group (HPF).
Circumference (μm) of the adipocyte from Retroperitoneal (RET) White Adipose Tissue in rats fed different diets during 8 weeksFigure 1
Circumference (μm) of the adipocyte from Retroperitoneal (RET) White Adipose Tissue in rats fed different diets during 8 
weeks. Values are means ± SEM (n = 8). A – Control Group (C): circumference = 127.35 ± 2.49 μm. B – Control + Fermented 
Product Group (CPF): circumference = 118.06 ± 1.75* μm. C – Hypercholesterolemic Diet Group (H): circumference = 
138.59 ± 2.37+ μm. D – Hypercholesterolemic + Fermented Product Group (HPF): circumference = 113.49 ± 2.03* μm. *p < 
0.05 comparing C × CPF and H × HPF; +p < 0.05 comparing C × H.
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since cholic acid promotes cholesterol absorption [28]
which was clearly shown in our study.
Fermented soy product administration resulted in a
decrease in food intake and body weight gain in hyperc-
holesterolemics rats, whereby the obtained values were
similar in the control group that received or not the fer-
mented soy product. Besides was observed a weight reduc-
tion of the white adipose tissue in hypercholesterolemic
rats treated with fermented soy product. Previous study
have found that the relative EPI weight in rats fed the cho-
lesterol-enriched diet and a chow diet plus fermented soy
product, tended to be lower than those in rats fed the
chow diet or a cholesterol-enriched diet [24].
Our results showed a significant reduction in the circum-
ference of EPI and RET depots when the ferment soy prod-
uct enriched with Enterococcus faecium and Lactobacillus
Jugurti was used, probably due to the significantly
decrease in lipogenesis rate and increase in lipolysis rate
in the RET and EPI, which were clearly shown in this study
(H × HPF and C × CPF). Previous work has indicated that
soy protein alters hormone balance and in turn accelerates
lipid metabolism [21] and suppress hepatic lipogenic
enzyme gene expression in Wistar fatty rats [32]. Our
results suggested that a small amount of soy protein
enriched with Enterococcus faecium and Lactobacillus Jugurti
could have the same effect of the previously reported.
Some studies have reported a hypocholesterolemic effect
with soy [19,33,34], whereas other studies have failed to
find this effect [35]. In our study, the treatment with fer-
mented soy product produced a significant lower in
plasma cholesterol and triglyceride concentrations in the
rats fed a hypercholesterolemic diet. Our results are in
agreement with those reported by Rossi et al. [25] and
Manzoni et al. [24], however in the last study was used the
fermented soy product supplemented with isoflavones.
Our results suggest that beyond isoflavone the Enterococ-
Circumference (μm) of the adipocyte from Epididymal (EPI) White Adipose Tissue in rats fed different diets during 8 weeksFigure 2
Circumference (μm) of the adipocyte from Epididymal (EPI) White Adipose Tissue in rats fed different diets during 8 weeks. 
Values are means ± SEM (n = 8). A – Control Group (C): circumference = 128.25 ± 2.05 μm. B – Control + Fermented Prod-
uct Group (CPF): circumference = 110.13 ± 1.42* μm. C – Hypercholesterolemic Diet Group (H): circumference = 122.69 ± 
1.73 μm. D – Hypercholesterolemic + Fermented Product Group (HPF): circumference = 110.12 ± 1.42* μm. *p < 0.05 com-
paring C × CPF and H × HPF.
DCBA
Table 3: Circumference (μm) of the adipocyte from 
Retroperitoneal (RET) and Epididymal (EPI) White Adipose 
Tissue in rats fed different diets during 8 weeks.
Circumference
Group RET EPI
C 127.35 ± 2.49 128.25 ± 2.05
CPF 118.06 ± 1.75* 110.13 ± 1.42*
H 138.59 ± 2.37+ 122.69 ± 1.73
HPF 113.49 ± 2.03* 100.12 ± 1.42*
Values are means ± SEM (n = 8).*p < 0.05 comparing C × CPF and H 
× HPF; +p < 0.05 comparing C × H. Control Group (C); Control + 
Fermented Product Group (CPF); Hypercholesterolemic Diet Group 
(H); and Hypercholesterolemic + Fermented Product Group (HPF).
Table 4: In vivo lipogenesis rate (μmol of 3H2O incorporated 
into lipid per gram of tissue per hour) in RET, EPI and liver in 
rats fed different diets during 8 weeks.
Groups RET EPI Liver
C 1,34 ± 0,29 0,59 ± 0,11 0,50 ± 0,10
CPF 0,29 ± 0,03* 0,14 ± 0,01* 0,61 ± 0,04
H 1,26 ± 0,11 1,30 ± 0,20+ 2,94 ± 0,37+
HPF 0,52 ± 0,03* 0,03 ± 0,05* ° 0,52 ± 0,03*
Values are means ± SEM (n = 8).*p < 0.05 comparing C × CPF and H 
× HPF; +p < 0.05 comparing C × H; °p < 0.05 comparing CPF × HPF. 
Control Group (C); Control + Fermented Product Group (CPF); 
Hypercholesterolemic Diet Group (H); and Hypercholesterolemic + 
Fermented Product Group (HPF).Page 4 of 9
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cholesterolemic effect. In most of the studies that reported
positive results, was more effective in hypercholestero-
lemic subjects than in normocholesterolemic subjects
[36,37].
There are multiple mechanisms by which soy protein
could modulate plasma lipid and lipoprotein concentra-
tions [37]. The interaction of protein with isoflavones and
other non-protein components may contribute to the
cholesterol-lowering effect of soy protein, since the isofla-
vones are structurally similar to estrogen and bind to the
estrogen receptor [20,38]. In previous studies [39-42],
reported that isoflavones have no effect when given sepa-
rately.
Others soy bioactive components such as amino acids,
minerals and the phytin acid could be acting actively in
the decrease of the cholesterol and triglycerides. Same
amino acids as the lysine increase the plasma cholesterol
concentration [43], while others as e.g. arginine [44], have
opposite action. This fact could partly be an explanation
of hypocholesterolemic effects of the soy, as it contains
good relation arginine/lysine [45]. The phytin acid
present in soy has chelant property for certain minerals,
such as for instance zinc. As the soy reduces the zinc
absorption, it provides a low relation zinc/copper, which
could reduce cholesterol. However, the concentration of
these substances was not evaluated in the present study.
It is known that the soy presents some antinutritious fac-
tors such as trypsin and chymotrypsin inhibitors, mineral
chelants and flatulence factor. Studies consider the possi-
bility that trypsin inhibitors are capable to increase the
cholecistochinin secretion that stimulates the liberation
and subsequent bile secretion [42,43]. The soy possesses
great fibre amount so this could be as well related to its
hypocholesterolemic effects [44]. In addition, as was
stated by Kritchevsky [45], animals fed soy protein excrete
more neutral and acidic steroids, and have increased activ-
ity of hepatic HMG CoA reductase and cholesterol 7alpha-
hydroxylase. In fact, Aoyama et al. [14] showed that rats
fed soy protein had an increase in fecal-fat excretion.
The addition of the Enterococcus faecium to soy also
could contribute to the decrease in cholesterol concentra-
tion in the group treated with hypercholesterolemic diet,
this effect was possibly due to the ability of the E. faecium
to reduce in 54% the cholesterol added to the adequate
culture medium [26], it has been proposed that the possi-
ble hypocholesterolemic effect of E. faecium involves inhi-
bition of exogenous cholesterol absorption from the diet
[24].
Rossi et al. [25], reported that administration of fer-
mented soy product enriched with Enterococcus faecium
and Lactobacillus Jugurti 10 ml/day, for 15 days lowered in
plasma cholesterol in 18,4%, however this difference dis-
appeared at the 30th day. As was stated by St-Onge et al.
[46], the fermented product containing several types of
bacteria, with indigestible carbohydrates and that produce
short-chain fatty acid that will alter cholesterol synthesis.
Also, the intestinal bacteria can bind bile acids to choles-
terol, resulting in the excretion of bile acid-cholesterol
complexes in the feces. Decreased bile acid recycling
through the enterohepatic circulation would result in cho-
lesterol uptake from the circulation into the liver for again
synthesis of bile acids.
The fermented soy product use promoted a significant
increase in HDL-cholesterol concentration, this is an
important factor that determining the reduction in the
risk of cardiovascular diseases. Similar results were
obtained by Fukushima and Nakano [47] and Rossi [25],
who showed that rats fed with high cholesterol diet, had
reduction in the total cholesterol and an increase in HDL
fraction with a daily intake of a probiotic product contain-
ing species of Lactobacillus, Streptococcus, and yeast.
The intake of 200 ml/day of the fermented soy milk, pro-
duced with Enterococcus Faecium and Lactobacillus Jugurti,
for 6 weeks led to a 10% increase in HDL-cholesterol level
Table 5: In vitro lipolysis rate (μmol of glycerol released/h.100 
mg) in RET and EPI in rats fed different diets during 8 weeks.
Groups RET EPI
C 0,34 ± 0,02 0,36 ± 0,01
CPF 0,51 ± 0,14* 0,29 ± 0,04
H 0,37 ± 0,02 0,39 ± 0,41
HPF 0,60 ± 0,003* 0,61 ± 0,04* °
Values are means ± SEM (n = 8).*p < 0.05 comparing C × CPF and H 
× HPF; +p < 0.05 comparing C × H; °p < 0.05 comparing CPF × HPF. 
Control Group (C); Control + Fermented Product Group (CPF); 
Hypercholesterolemic Diet Group (H); and Hypercholesterolemic + 
Fermented Product Group (HPF).
Table 6: Lipid parameters (Plasma Triglycerides, Total 
Cholesterol and HDL-Cholesterol Concentrations – mg/dl) in 
rats fed different diets during 8 weeks.
Groups Triglycerides Cholesterol HDL-cholesterol
C 122.67 ± 15.08 62.17 ± 3.07 18.66 ± 1.76
CPF 157.29 ± 16.36 69.28 ± 2.61 27.14 ± 1.71*
H 177.83 ± 15.78+ 108.67 ± 5.22+ 20.00 ± 1.26
HPF 94.83 ± 6.36* 91.40 ± 2.13* ° 22.33 ± 1.02
Values are means ± SEM (n = 8).*p < 0.05 comparing C × CPF and H 
× HPF; +p < 0.05 comparing C × H; °p < 0.05 comparing CPF × HPF. 
Control Group (C); Control + Fermented Product Group (CPF); 
Hypercholesterolemic Diet Group (H); and Hypercholesterolemic + 
Fermented Product Group (HPF).Page 5 of 9
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holm-Larsen et al. [49], reported that the consumption of
yogurt fermented with different probiotics had variable
effects on LDL cholesterol in obese subjects. Previous
studies that used probiotic mixture containing Lactobacil-
lus acidophilus, Lactobacillus casei, and Bifidobacterium bifi-
dum, but found no significant effect on body weight, fat
deposition, plasma cholesterol levels [50], suggesting that
hypolipidemic effect is dependent on the type of probiot-
ics.
In addition, the low serum cholesterol concentrations
observed in rats treated with HPF diet as compared to H
diets; might be due to the reduction of lipogenesis. Thus,
the reduced biosynthesis of fatty acids in turn will reduce
the production of VLDL particles, thus limiting the forma-
tion of LDL particles and resulting in low serum triglycer-
ides and cholesterol concentrations [51].
Further studies are needed to clarify whether this effect is
due to the soy protein or to the Enterococcus faecium and
Lactobacillus Jugurti and whether other types of probiotic
mixtures containing different bacterial strains, other than
used in the present study, have effects on lipid metabo-
lism deserves further investigation.
Conclusion
The present study showed that 1 ml/day/rat of fermented
soy product enriched with Enterococcus faecium and
Lactobacillus Jugurti induces an improvement in lipid
profile and reduction in visceral and central adiposity.
Methods
Animals
Thirty-two adults male Wistar rats, weighing 210 ± 10 g
were housed in individual cages. The animals were kept at
an environmental temperature of 23 ± 2°C in a 12 h light/
dark controlled room. All animal procedures were per-
formed according to principles in the Guide for the Care
and Use of Laboratory Animals [52].
Diets
Before beginning the experiment, the animals were sub-
mitted during five days to an adaptive period of flavour
conditioning: during two days the animals received the
sweet solution; afterwards they received during two days
the sweet and acid solution, and finally the placebo prod-
uct. The animals were randomly divided into four groups
(n = 8) as follows: Control Group (C); Control + Fer-
mented Product Group (CPF); Hypercholesterolemic diet
group (H); and Hypercholesterolemic + Fermented Prod-
uct Group (HPF). The control groups were fed with a
chow diet (Nuvilab®). The animals of the H and HPF
groups were fed with a chow diet enriched in cholesterol
0,15% (w/w), of Sigma C 8503 cholesterol. The choles-
terol was diluted in ethyl ether P.A and stabilized with 10
ppm of butylated hydroxytoluene-BHT. The HPF and CPF
groups received an intragastric administration of 1 ml of
fermented product daily, during the 8 weeks of the study.
Body weight gain and total food intake was measured.
Preparation of the fermented product
The fermented soy product was prepared according to the
methodology described by Rossi et al. (1999), and was
added in 1.5% (v/v) of the Enterococcus faecium CRL 183
culture and 1.5% (v/v) of Lactobacillus Jugurti 416 culture.
Quantification of the viable cells in the finished fer-
mented product was performed using the specific M 17-
agar and MRS-agar media of culture. The colonies formed
were counted and their morphological characteristics
were recorded [26].
Experimental Procedure
After 8 weeks of treatment the animals were killed by
decapitation. Trunk blood was collected in a heparinized
tube and was centrifuged for 15 min at 2500 rev./min.
Retroperitoneal (RET) and Epididymal (EPI) white adi-
pose tissues were immediately removed and weighed.
Adipocyte size
A fragment (100 mg) of RET and EPI was fixed in 0.2 M
collidine buffer pH 7.4, containing 2% of osmium tetrox-
ide at 37°C. After 24 hours, they were washed with
warmed saline as described by Hirsch & Gallian (1968).
The adipocyte circumference was measured using image
analysis software (Image Pro Plus) and expressed as μm.
Plasma lipids
Plasma was used to measure triglycerides (TG), total cho-
lesterol (TC) and HDL-cholesterol. For these measure-
ments we used commercial Kits from Labtest Diagnostic
S.A.
Measurements of the lipogenesis rate
All animals were killed by decapitation 1 h after an intra-
peritoneal injection of 3 mCi 3H2O in a volume of 0.3 ml
for the determination of the in vivo lipogenesis rate. The
"de novo" lipogenic (fatty acid synthesis) rate was deter-
mined by the incorporation of 3H2O into saponified lip-
ids according to the method of Robinson & Williamson
[53]. Tissues samples were digested in 3 ml of 30% KOH
and 3 ml of ethanol for at least 2 h at 70°C in capped
tubes for the lipids to saponify. After cooling, 2 ml of 12
N H2SO4 was added, and lipid was extracted three times
with 10 ml of petroleum ether [54]. The combined petro-
leum ether plus extracts was washed with 2 ml of distilled
water and evaporated to dryness. The extracted fatty acids
were dissolved in 5 ml of scintillation liquid, and radioac-
tivity of 20 μl serum samples was counted for the determi-
nation of specific activity. The rate of lipogenesis wasPage 6 of 9
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ids per gram per hour. The lipid content of the tissue was
determined by the gravimetric method [55].
Determination of lipolysis rate "in vitro"
Tissue fragments (about 100 mg) of RET and EPI were
used for "in vitro" determination of glycerol release, an
index of lipolytic rate [56]. The samples were minced into
small fragments and incubated for 1 h at 37°C under con-
tinuous shaking in Ca2+-free Krebs-Henseleit solution
containing 2% (w/v) bovine albumin (fraction V-essen-
tially fatty acid-free), pH 7.4. Lipolysis was interrupted by
placing the vials on ice. The tissue fragments were then
removed and the glycerol content in the medium was
determined enzymatically by the method of Eggstein and
Kreutz [57]. The results were expressed as μmol of glycerol
released/h.100 mg of tissue.
Statistical Analysis
Results are expressed as means ± standard error of the
means. Data were analyzed using two-way ANOVA to test
the effects of diets, fermented soy product and their inter-
actions, following by Tukey-Kramer multiple comparison
test. Significance was accepted at the p < 0.05 level.
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